## REVIEW ARTICLE

# Perinatal Tuberculosis

Arvind Shenoi<sup>1</sup>, Kavitha HR<sup>2</sup>

## Abstract

Tuberculosis (TB) is a major contributor to disease burden globally. Congenital tuberculosis is a life-threatening disease in neonates with higher mortality rate. Perinatal transmission of infection occurs in utero or during delivery. It is difficult to differentiate congenital infection from postnatal. Cantwell criteria is used for the diagnosis of congenital infection. As symptoms are nonspecific congenital tuberculosis has to be actively considered as a possibility to diagnose it. Isolation of *Mycobacterium tuberculosis* organism either in culture or acid-fast bacilli (AFB) smear is very essential for the diagnosis. After the diagnosis of congenital tuberculosis treatment has to be initiated without delay. Breastfeeding should be encouraged among mothers on treatment for latent tuberculosis and after two weeks of treatment for active TB.

Keywords: Congenital tuberculosis, Diagnosis, Perinatal transmission, Treatment.

Pediatric Infectious Disease (2019): 10.5005/jp-journals-10081-1107

## **E**PIDEMIOLOGY

Mycobacterium tuberculosis is the causative organism of TB and is a major public health problem. "The World Health Organization (WHO) in its 2018 report, estimated that out of 10 million cases of TB in 2017, about 1 million occurred among children less than 15 years. There were 234,000 deaths of children due to tuberculosis and 40,000 deaths in HIV infected children".<sup>1</sup>

## TUBERCULOSIS OF FETUS OR NEWBORN

#### Definitions

There are two types of neonatal tuberculosis namely congenital TB and postnatally acquired TB. Neonatal TB is a serious infection and the mortality rate is about 50%.<sup>2-4</sup> Congenital TB is contracted during pregnancy or at the time of childbirth and cause disease afterward. Perinatal TB is a preferred term which includes true congenital disease. The diagnostic criteria for congenital tuberculosis were put forth by Beitzke in 1935. It was subsequently revised by Cantwell in the year 1994.<sup>5</sup>

#### Diagnostic Criteria<sup>5</sup>

Proven tuberculous lesions plus one of the following:

- · The tuberculous lesion in a newborn baby in the first week of life
- Primary liver complex or caseating hepatic granulomas
- Maternal genital tract or placental TB
- Exclusion of postnatal transmission by a thorough investigation of contacts.

Postnatal TB is contracted after birth either by inhalation of TB bacilli or by ingestion of infected breast milk and the infant subsequently present with signs and symptoms of tuberculosis along with radiographic findings.<sup>6</sup>

It is difficult to differentiate between true congenital TB and those acquired postnatally, in general, clinical presentation and management remain the same between two groups.

## **TRANSMISSION AND PATHOGENESIS**

Perinatal transmission of tuberculosis is a possibility through a multitude of ways. Most commonly associated with endometrial tuberculosis or disseminated infection in mother. The hematogenous spread can happen via the umbilical vein or by infected amniotic fluid aspiration, or ingestion of infected secretions.<sup>2,4</sup>

#### <sup>1</sup>Head, <sup>2</sup>Fellow

<sup>1</sup>Department of Neonatology, Cloudnine Hospital, Bengaluru, Karnataka, India

<sup>2</sup>Department of Neonatology and Pediatrics, Cloudnine Hospital, Bengaluru, Karnataka, India,

**Corresponding Author:** Arvind Shenoi, Head, Department of Neonatology, Cloudnine Hospital, Bengaluru, Karnataka, India, e-mail: arvind.shenoi@gmail.com

**How to cite this article:** Shenoi A, Kavitha HR. Perinatal Tuberculosis. Pediatr Inf Dis 2019;1(1):30-33.

#### Source of support: Nil

Conflict of interest: None

Primary complex in the liver along with caseating granuloma is the definitive lesion of congenital tuberculosis. The organisms can spread beyond the liver into the systemic circulation causing disseminated infection involving GI tract, spleen, kidney, adrenals, bone marrow, meninges, and skin. Rupture of the placental tuberculous lesion into amniotic fluid may cause primary foci in the lungs or GI tract if the fetus inhales or ingest infected amniotic fluid. Neonate can present as sepsis-like syndrome if there is massive dissemination.<sup>6</sup>

## CLINICAL PRESENTATION/RADIOGRAPHIC FINDINGS

Perinatal TB usually manifest at a median age of 24 days, but occasionally noted at birth ranging from 1 to 84 days.<sup>5</sup> Hepatosplenomegaly and respiratory distress are the most common presentation of congenital tuberculosis followed by poor feeding, fever, failure to thrive, irritability, lethargy, cough, abdominal distension and low birth weight.<sup>3,6,7</sup> Neonatal TB may present in the form of septicemia, persistent or recurrent pneumonia, meningitis, lymphadenopathy, jaundice, ascites, disseminated intravascular coagulation, otitis media, osteomyelitis, paravertebral abscess and cold abscess.<sup>8</sup>

Sometimes, the initial manifestation is very similar to sepsis, the clinician should have a high index of suspicion if a sick newborn fails to improve with antibiotics and has negative microbiological and serological test results for infections. About 50% neonates have miliary disease pattern in chest X-ray, rests have adenopathy and parenchymal infiltrates.<sup>6</sup>

<sup>©</sup> The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons. org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and non-commercial reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

## DIAGNOSIS

Assessment of maternal risk factor for TB is very important in suspected congenital tuberculosis. Placental examination and culture for TB bacilli should be done if the mother presents with inexplicable bronchitis, pneumonia, meningeal disease, endometritis or unusual uterine bleeding. If the placenta is not available for examination, uterine dilatation and curettage should be considered because endometrial culture often yields positive results.<sup>6</sup> HIV testing for a mother is very important in suspected congenital tuberculosis. The diagnosis of congenital tuberculosis sometimes helps in the detection of undiagnosed maternal TB.<sup>9</sup>

Confirmation of tuberculosis in the neonate is done by testing body fluids for positive acid-fast bacilli smear and cultures such as tracheal aspirates, gastric aspirates, and tissue biopsy. Cerebrospinal fluid analysis for acid-fast bacilli is very essential because tubercular meningitis occurs in 1/3rd cases of congenital TB.<sup>6</sup>

The PCR of bronchoalveolar lavage fluid is an efficient modality for diagnosis in neonates.<sup>10</sup> The Mantoux test in neonates is often negative in the initial stages but frequently becomes positive after a few months. Gastric and tracheal aspirates are far more sensitive than the tuberculin skin test. Gastric aspirates are positive in 80% whereas, Mantoux is positive in less than 15% of cases.<sup>3,5</sup>

"Some newborns may have positive interferon-gamma release assay, but due to the limited data on the reliability of a negative test results IGRA is not recommended by AAP in children less than 2 years of age".<sup>6</sup>

Ultrasound liver is crucial in case of suspected congenital TB. Liver biopsy, though invasive should be considered if abnormal features are found in ultrasound or if there is a diagnostic dilemma to look for caseating granulomas.<sup>11</sup> Liver biopsy is 100% sensitive in the diagnosis of congenital tuberculosis.<sup>3</sup>

Newer methods such as LED fluorescence microscopy and *mycobacterium* growth indicator tube (MGIT) are used for rapid diagnosis in developed countries. LED fluorescence microscopy is more sensitive and specific in the identification of TB bacilli compared to the existing older modalities.<sup>12</sup> Gene Xpert is a rapid diagnostic tool used in highly TB prevalent areas including multidrug-resistant TB.<sup>13</sup>

## TREATMENT

As soon as proper culture samples are obtained in a suspected neonatal TB, antituberculosis treatment should be started promptly. Currently, there is no specific RNTCP treatment guidelines exist for perinatal tuberculosis. The AAP recommendation for the treatment of neonatal tuberculosis includes four-drug regimen for the first 2 months (intensive phase)—isoniazid (INH), rifampin (RIF), pyrazinamide (PZA) and either ethambutol (EMB) or an aminoglycoside such as amikacin. Amikacin is most commonly used instead of Ethambutol because neonates are at higher risk of developing meningitis or disseminated disease, and Amikacin has better CNS penetration ability and bactericidal activity.<sup>14</sup>

After the completion of the intensive phase, the recommended duration of continuation phase is 7–10 months of Isoniazid and Rifampin therapy. The total duration of treatment for neonatal tuberculosis is usually 9–12 months.<sup>14</sup>

Prednisone (2 mg/kg/day) should be administered for 4–6 weeks if TB meningitis is suspected. The drug is gradually tapered and stopped.<sup>14</sup>

## Prognosis

The mortality rate of congenital tuberculosis even with effective treatment is 25–50%, hence, the prognosis is guarded.<sup>6</sup> There are several reasons for high morbidity and mortality associated with congenital tuberculosis;

- Nonspecific signs and symptoms of the disease, which results in a delay in diagnosis.<sup>3,15,16</sup>
- The false negativity of tuberculin test in newborns poses another challenge compared to in older children, which cause further delay in diagnosis.<sup>8</sup>
- Disseminated diseases such as meningeal and miliary tuberculosis are common in neonates than other age groups.<sup>15,17</sup>
- The immune system is relatively immature in neonates, so they are at risk to develop tuberculosis disease.<sup>18,19</sup>

#### **MATERNAL TUBERCULOSIS**

#### Latent Tuberculosis Infection (LTBI) in Pregnancy

Treatment of latent TB in pregnant women should be deferred until 3 months after delivery to reduce the risk of hepatitis.<sup>20</sup>

#### **Active Tuberculosis Disease in Pregnancy**

Active TB in pregnancy is associated with adverse fetal and maternal outcomes. Hence pregnant mother once diagnosed with active TB, prompt treatment should be initiated. Active TB disease treatment in pregnancy includes 2 months of intensive phase with isoniazid, rifampin, and ethambutol, followed by 7 months of isoniazid and rifampin, the total duration of treatment is 9 months.<sup>21,22</sup>

#### MANAGEMENT OF AN EXPOSED NEONATE

Mother with active pulmonary TB can transmit the infection to her newborn, so at the time of delivery baby born to a mother with suspected or known active disease should be separated until both have been evaluated.<sup>14</sup> Management is summarized in Table 1.

- If both mother and neonate have active pulmonary TB, both should be started on ATT, mother and baby need not be separated as long as both are adherent and mother should use a mask until she is noninfectious.
- If the mother has pulmonary tuberculosis and neonate has a latent infection without active disease, the mother should be treated for active TB disease and baby should be started on lsoniazid prophylaxis. Separation of mother and baby is not required if they are compliant to treatment and mother should follow infection control measures such as to wear a mask.
- If the mother has active pulmonary TB and there is no proof of active TB disease or latent infection in neonate, the mother should be treated with ATT for active disease and baby for latent infection with Isoniazid for 3 to 4 months. Mother and baby can be together provided they are adherent, and the mother should use a mask.
- Once the infant completes 3 to 4 months of Isoniazid prophylaxis, tuberculin skin test should be done:
- If the infant's repeat tuberculin test is positive, investigations should be carried out to look for active disease and the infant should be treated for either active disease or latent infection based on the tests result.
- If the infant's repeat skin test is negative, Isoniazid can be stopped.

	Mother and baby both— active pulmonary TB	Mother—active TB disease Baby—no disease, skin test positive	Mother—active TB disease Baby—no disease/no latent infection
Treatment	Mother—ATT Baby—ATT	Mother—ATT Baby—Isoniazid prophylaxis	Mother—ATT Baby- INH for 3–4 months followed by MTX test. If MTX negative stop INH by 3 months. If Mtx is positive, search for disease. If the disease is positive then treat as congenital TB, if no disease give INH for 9 months
Isolation	Separation avoided Advised if MDR-TB, non- compliant to therapy, the mother has contagious TB before starting ATT	Separation avoided Advised if MDR-TB, non- compliant to therapy, the mother has contagious TB before starting ATT	Separation avoided Advised if MDR-TB, non- compliant to therapy, the mother has contagious TB before starting ATT
Barrier method	Face mask	Face mask	Face mask
	≤20 weeks Advised MTP	• Omit k • Replac	>20 weeks bdified Cat IV anamycin; Add PAS till delivery ce PAS with kanamycin after y and continue till the end of IP
MTP Start/continu Cat IV	e Start modifi ≤12 weeks: Omit kanan add PAS >12 weeks:	nycin and ethionamide;	

- If the mother is still contagious, both infant and mother require re-evaluation and consultation with a TB expert
- If MDRTB is suspected, a TB expert should be consulted (Flowchart 1).
- RNTCP, IAP and WHO recommends INH prophylaxis for 6 months for an infant with latent TB infection.<sup>23-25</sup>

#### BREASTFEEDING

Breastfeeding should be encouraged for mothers on latent TB infection treatment and after at least two weeks of treatment for active Tuberculosis.<sup>14</sup>

The first line ATT drugs are secreted in small amount in breast milk (less than 20% of therapeutic infant dose) and will not cause any toxic effects on breastfed infants.<sup>20,21,26</sup>

Infants on exclusive breastfeeding receiving Isoniazid should be supplemented with pyridoxine.<sup>14</sup>

#### PREVENTION

BCG vaccination is protective against tuberculous meningitis and disseminated form of TB. In infants receiving chemoprophylaxis BCG vaccine is recommended.<sup>23,24</sup> American Academy of Pediatrics recommends BCG vaccination after INH prophylaxis and if follow-up



is not possible then at birth itself.<sup>14</sup> Whereas, RNTCP and IAP advocate BCG administration at birth even for those receiving Isoniazid prophylaxis after excluding congenital TB.<sup>23,27</sup> "WHO recommends BCG vaccination for neonates born to mother with pulmonary TB if an infant is asymptomatic, has no immunological evidence of TB and is HIV negative".<sup>28</sup> Children in highly TB prevalent countries are more prone to get infection early in their life, so BCG should be administered as soon as possible.

#### CONCLUSION

Perinatal TB carries a high mortality rate because of the delay in diagnosis and prompt initiation of treatment. A high index of suspicion, a detailed maternal history, and thorough evaluation of mother and baby is very crucial in establishing the diagnosis. Work up for congenital tuberculosis must include CSF analysis to look for tuberculous meningitis and disseminated disease. Early diagnosis and timely commencement of antitubercular therapy are very critical in reducing the morbidity and mortality associated with the disease. If multidrug-resistant TB is suspected consultation with TB expert is very important.

#### REFERENCES

- 1. World Health organization .Global Tuberculosis Report 2018 .http:// www.who. Int/tb / publication /global\_report/en.
- 2 Starke JR. Tuberculosis in childhood and pregnancy. In: Tuberculosis: current concepts and treatment, 2nd ed, Friedman LN (Ed), CRC Press, Boca Raton 2000.
- 3 Hageman J, Shulman S, Schreiber M, et al. Congenital tuberculosis: critical reappraisal of clinical findings and diagnostic procedures. Pediatrics 1980;66:980.
- 4 Manji KP, Msemo G, Tamim B, Thomas E. Tuberculosis (presumed congenital) in a neonatal unit in Dar-es-Salaam, Tanzania. J Trop Pediatr 2001; 47:153
- 5 Cantwell M, Shehab Z, Costello A, et al.Brief report: congenital tuberculosis. N Engl J Med 1994;330(15):1051-1054
- 6 Heather Y.Highsmith and Jeffrey R.Starke.Tuberculosis. Cloherty and Stark's manual of neonatal care, 8th edition, 2017:738-754
- 7 Chotpitayasunondh T, Sangtawesin V, Congenital tuberculosis. J Med Assoc Thai 2003; 86 (Suppl 3): S689-695.
- 8 Vallejo J, Ong LT, Starke JR. Clinical features, diagnosis and treatment of tuberculosis in infants. Pediatrics 1994;94:1-7
- 9 Laibl VR, Sheffield JS. Tuberculosis in pregnancy. Clin Perinatol 2005; 32:739.
- 10 Parakh A, Saxena R, Thapa R, et al. Perinatal 11. Tuberculosis: four cases and use of broncho-alveolar lavage. Ann Trop Paediatr 2011; 31:75-80.

- 11 Manou Irmina, Saramba, Dongchi Zhao. A Perspective of the Diagnosis and management of congenital tuberculosis. Journol of Pathogens 2016; Article ID 8623825.
- 12 World Health Organization. 12. Fluorescent light emitting diode (LED) microscopy for diagnosis of tuberculosis. Policy statement. Geneva: World Health Organization; 2011.
- 13 Rossau R, Traore H, De Beenhouwer H, et al. Evaluation of the INNO-LiPA Rif. TB assay, a reverse hybridization assay for the simultaneous detection of *Mycobacterium tuberculosis* complex and its resistance to rifampin. Antimicrob Agents Chemother 1997; 41: 2093-2098.
- 14 American Academy of Pediatrics. Red Book: 2018 Report of the Committee on Infectious Diseases, 31st ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Itasca, IL 2018
- 15 Schaaf HS, Gie RP, Beyers N, et al. Tuberculosis in infants less than 3 months of age. Arch Dis Child 1993; 69:371-374
- 16 Myers JP, Perlstein PH, Light IJ, et al. Tuberculosis in pregnancy with fatal congenital infection. Pediatrics 1981;67:89-94
- 17 Rich AR. The influence of sex and age: the pathogenesis of tuberculosis. Springfield (IL): Charles C Thomas 1951:182-251
- 18 Kondo S, Ito M, Kageyama S. Infants 12 month-old or less as a high risk group in tuberculosis comparison of clinical data with those in children aged one to three years. Kekkaku 2001;76(5):407-411
- 19 Kondo S, Ito M. Difficulties in the treatment of tuberculosis in infants. Kekkaku 2003;78(1):1-3.
- 20 Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000;49:1.
- Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016;63:e147.
- 22 Snider DE Jr, Layde PM, Johnson MW, et al. Treatment of tuberculosis during pregnancy. Am Rev Respir Dis 1980;122:65.
- 23 Updated IAP RNTCP Ped TB Guidelines 2019; Developed by Revised National Tuberculosis Control and Indian Academy of Pediatrics; Central TB division, Ministry of Health and Family Welfare, New Delhi, India 2019;1-87.
- 24 Kumar A, Gupta D, Nagaraja SB, et al. Updated national guidelines for pediatric tuberculosis in India, 2012. Indian Pediatr 2013;50:301-306.
- 25 World Health Organization. Treatment of tuberculosis guidelines, 4th ed. Geneva: WHO; 2009. WHO/HTB/ TB/2009.420
- 26 Briggs GG, Freeman, RK, Yaffe SJ. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk, 7th ed, Lippincott Williams and Wikins, Philadelphia 2005.
- 27 Working Group on Tuberculosis, Indian Academy of Pediatrics (IAP). Consensus statement on childhood tuberculosis. Indian Pediatr 2010; 47:41-54.
- 28 World Health Organization position paper on BCG vaccination, February 2018.https://www.who.int/policy/bcg.